Biomira submits Tru-Scint in Canada
This article was originally published in Clinica
Biomira has made a New Drug Submission to the Canadian Health Protection Branch for its Tru-Scint AD imaging agent. The submission covers the detection of recurrent breast cancer and primary, residual or recurrent ovarian cancer. The Canadian agency has indicated it will give the technetium-99m-labelled monoclonal antibody priority evaluation status, since the active substance may provide more effective diagnosis of serious and life threatening diseases than currently used protocols.